CAR T-cell treatment of high-risk multiple myeloma: will there be a cure?
作者信息
Gahrton Gösta
机构信息
Department of Medicine, Karolinska Institutet, Huddinge, Stockholm, Sweden.
出版信息
Haematologica. 2023 Oct 1;108(10):2568-2569. doi: 10.3324/haematol.2023.282896.
Abstract
摘要
相似文献
1
CAR T-cell treatment of high-risk multiple myeloma: will there be a cure?嵌合抗原受体T细胞疗法治疗高危多发性骨髓瘤：有望治愈吗？
Haematologica. 2023 Oct 1;108(10):2568-2569. doi: 10.3324/haematol.2023.282896.
2
CAR T-cell therapy against B-cell maturation antigen in multiple myeloma.用于治疗多发性骨髓瘤的靶向B细胞成熟抗原的嵌合抗原受体T细胞疗法
Clin Adv Hematol Oncol. 2018 Dec;16(12):804-806.
3
Impact of high-risk disease on the efficacy of chimeric antigen receptor T-cell therapy for multiple myeloma: a meta-analysis of 723 patients.高危疾病对嵌合抗原受体T细胞疗法治疗多发性骨髓瘤疗效的影响：一项对723例患者的荟萃分析
Haematologica. 2023 Oct 1;108(10):2799-2802. doi: 10.3324/haematol.2022.282510.
4
Chimeric antigen receptor T cell targeting B cell maturation antigen immunotherapy is promising for multiple myeloma.嵌合抗原受体 T 细胞靶向 B 细胞成熟抗原免疫疗法对多发性骨髓瘤具有广阔的应用前景。
Ann Hematol. 2019 Apr;98(4):813-822. doi: 10.1007/s00277-018-03592-9. Epub 2019 Jan 28.
5
Chimeric Antigen Receptor T-Cell Therapeutics for Multiple Myeloma: Moving Into the Spotlight.用于多发性骨髓瘤的嵌合抗原受体T细胞疗法：走向聚光灯下。
Cancer J. 2021;27(3):205-212. doi: 10.1097/PPO.0000000000000525.
6
Chimeric Antigen Receptor T Cells in Multiple Myeloma.嵌合抗原受体 T 细胞在多发性骨髓瘤中的应用。
Hematol Oncol Clin North Am. 2023 Dec;37(6):1089-1105. doi: 10.1016/j.hoc.2023.05.008. Epub 2023 Aug 8.
7
Preclinical Evaluation of Allogeneic CAR T Cells Targeting BCMA for the Treatment of Multiple Myeloma.同种异体嵌合抗原受体 T 细胞靶向 BCMA 治疗多发性骨髓瘤的临床前评估。
Mol Ther. 2019 Jun 5;27(6):1126-1138. doi: 10.1016/j.ymthe.2019.04.001. Epub 2019 Apr 8.
8
Multiple Myeloma, Targeting B-Cell Maturation Antigen With Chimeric Antigen Receptor T-Cells.多发性骨髓瘤：嵌合抗原受体 T 细胞靶向 B 细胞成熟抗原
Cancer J. 2019 May/Jun;25(3):208-216. doi: 10.1097/PPO.0000000000000379.
9
Driving CARs to new places: locally produced BCMA CAR T cells to treat multiple myeloma.驾驶CAR驶向新领域：本地生产的靶向B细胞成熟抗原的嵌合抗原受体T细胞治疗多发性骨髓瘤
Haematologica. 2023 Jul 1;108(7):1721-1723. doi: 10.3324/haematol.2022.282053.
10
Subsequent anti-myeloma therapy after maturation antigen (BCMA) chimeric antigen receptor (CAR)-T cell (HDS269B) treatment in patients with relapsed/refractory multiple myeloma.复发/难治性多发性骨髓瘤患者接受成熟抗原（BCMA）嵌合抗原受体（CAR）-T细胞（HDS269B）治疗后的后续抗骨髓瘤治疗。
Am J Hematol. 2022 Dec;97(12):E478-E481. doi: 10.1002/ajh.26745. Epub 2022 Oct 17.
本文引用的文献
1
Impact of high-risk disease on the efficacy of chimeric antigen receptor T-cell therapy for multiple myeloma: a meta-analysis of 723 patients.高危疾病对嵌合抗原受体T细胞疗法治疗多发性骨髓瘤疗效的影响：一项对723例患者的荟萃分析
Haematologica. 2023 Oct 1;108(10):2799-2802. doi: 10.3324/haematol.2022.282510.
2
GPRC5D CAR T cells (OriCAR-017) in patients with relapsed or refractory multiple myeloma (POLARIS): a first-in-human, single-centre, single-arm, phase 1 trial.复发或难治性多发性骨髓瘤患者中的GPRC5D嵌合抗原受体T细胞（OriCAR-017）（北极星研究）：一项首次人体、单中心、单臂1期试验。
Lancet Haematol. 2023 Feb;10(2):e107-e116. doi: 10.1016/S2352-3026(22)00372-6.
3
Updated results from a matching-adjusted indirect comparison of efficacy outcomes for ciltacabtagene autoleucel in CARTITUDE-1 versus idecabtagene vicleucel in KarMMa for the treatment of patients with relapsed or refractory multiple myeloma.CARTITUDE-1 中 cilta-cabtagene autoleucel 与 KarMMa 中 idecabtagene vicleucel 治疗复发/难治性多发性骨髓瘤患者的疗效结局的匹配调整间接比较的更新结果。
Curr Med Res Opin. 2023 Jan;39(1):81-89. doi: 10.1080/03007995.2022.2139052. Epub 2022 Nov 15.
4
Autologous NK cells as consolidation therapy following stem cell transplantation in multiple myeloma.自体自然杀伤细胞作为多发性骨髓瘤干细胞移植后的巩固治疗。
Cell Rep Med. 2022 Jan 28;3(2):100508. doi: 10.1016/j.xcrm.2022.100508. eCollection 2022 Feb 15.
5
Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study.西达基奥仑赛，一种针对 B 细胞成熟抗原的嵌合抗原受体 T 细胞疗法，用于治疗复发或难治性多发性骨髓瘤患者（CARTITUDE-1）：一项 1b/2 期开放标签研究。
Lancet. 2021 Jul 24;398(10297):314-324. doi: 10.1016/S0140-6736(21)00933-8. Epub 2021 Jun 24.
6
Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma.伊达比星脂质体注射用多柔比星治疗复发/难治性多发性骨髓瘤
N Engl J Med. 2021 Feb 25;384(8):705-716. doi: 10.1056/NEJMoa2024850.
7
Autologous/reduced-intensity allogeneic stem cell transplantation vs autologous transplantation in multiple myeloma: long-term results of the EBMT-NMAM2000 study.自体/减低强度异基因干细胞移植与多发性骨髓瘤的自体移植：EBMT-NMAM2000 研究的长期结果。
Blood. 2013 Jun 20;121(25):5055-63. doi: 10.1182/blood-2012-11-469452. Epub 2013 Mar 12.
8
Graft-versus-myeloma effect.
Lancet. 1996 Aug 3;348(9023):346. doi: 10.1016/s0140-6736(05)64525-4.
9
Graft-versus-myeloma effect: proof of principle.
Blood. 1996 Feb 1;87(3):1196-8.
10
Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors.通过由抗体结合域以及免疫球蛋白和T细胞受体的γ或ζ亚基组成的嵌合单链对细胞毒性淋巴细胞进行特异性激活和靶向。
Proc Natl Acad Sci U S A. 1993 Jan 15;90(2):720-4. doi: 10.1073/pnas.90.2.720.
Zotero 插件